<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To examine treatment and <z:chebi fb="105" ids="17234">glucose</z:chebi> control in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients with and without <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and to explore differences in markers for <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and beta cell function </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A community-based, cross-sectional observational study was carried out at the <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:mp ids='MP_0002055'>diabetes</z:mp> outpatient clinic in primary health care, Skara, Sweden </plain></SENT>
<SENT sid="2" pm="."><plain>The subjects were <z:hpo ids='HP_0000001'>all</z:hpo> the 400 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (202 men, 198 women) who underwent annual follow-up from May 1992 through September 1993; 204 of these also had <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The patients with both type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> had a higher b.m.i </plain></SENT>
<SENT sid="4" pm="."><plain>(mean; 28.9 kg m(-2) (s.d.; 4.4) vs. 27.4 kg m(-2)(4.6)), higher <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (2.0 mmol l(-1)(1.1) vs. 1.7 mmol l(-1)(1.1)), higher <z:chebi fb="15" ids="39026">LDL</z:chebi>/<z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> ratio (4.3(1.4) vs. 4.1(1.2)) and higher fasting insulin (8.5 mU l(-1)(1.1) vs. 6.6 mU l(-1)(1.1)) </plain></SENT>
<SENT sid="5" pm="."><plain>Conversely, <z:chebi fb="105" ids="17234">glucose</z:chebi> levels were lower; HbA1c (6.4%(1.4) vs. 6.8%(1.6)) and fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> (8.1 mmol l(-1)(2.3) vs. 8.9 mmol l(-1)(2.7)) than in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> alone </plain></SENT>
<SENT sid="6" pm="."><plain>By the homeostasis model assessment (HOMA), patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> alone had more impaired beta cell function </plain></SENT>
<SENT sid="7" pm="."><plain>They also had a higher frequency of insulin treatment (20% vs. 12%) and were less often treated non-pharmacologically (33% vs. 50%) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:hpo ids='HP_0000822'>hypertension</z:hpo> constitute a high risk category with a more atherogenic risk factor profile related to the <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> syndrome </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> without <z:hpo ids='HP_0000822'>hypertension</z:hpo> seem to constitute a subgroup of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with predominately impaired beta cell function </plain></SENT>
</text></document>